论文部分内容阅读
目的通过观察T淋巴细胞亚群水平的改变,探讨奥沙利铂联合卡培他滨对中晚期胃癌术后患者T淋巴细胞亚群水平的影响。方法选取2014年9月至2016年9月Ⅱ期、Ⅲ期胃癌患者86例,将其随机分为两组,每组43例。对照组采用奥沙利铂联合亚叶酸钙、氟尿嘧啶进行化疗,而观察组应用奥沙利铂联合卡培他滨治疗,两组均连续治疗2个疗程,每个疗程2周。比较两组治疗后T淋巴细胞亚群水平,并观察两组化疗期间不良反应发生情况。结果治疗后,观察组CD3~+、CD4~+、CD8~+水平分别为(68.84±5.73)%、(44.14±4.82)%、(47.15±4.17)%,均明显高于对照组的(58.95±5.26)%、(35.28±4.21)%、(38.61±3.82)%,差异有统计学意义(P<0.05);观察组不良反应中骨髓抑制、胃肠道反应发生率分别为20.93%、18.60%,较对照组的39.53%、37.21%均明显降低,差异有统计学意义(P<0.05)。结论奥沙利铂联合卡培他滨可明显提高中晚期胃癌术后患者T淋巴细胞亚群水平,改善细胞免疫功能,并缓解不良反应。
Objective To investigate the effect of oxaliplatin combined with capecitabine on the level of T lymphocyte subsets in postoperative patients with advanced gastric cancer by observing the changes of T lymphocyte subsets. Methods Totally 86 patients with stage Ⅱ and stage Ⅲ gastric cancer from September 2014 to September 2016 were randomly divided into two groups (43 in each group). The control group received oxaliplatin combined with leucovorin and fluorouracil for chemotherapy, while the observation group received oxaliplatin combined with capecitabine. The two groups were treated for two consecutive courses of 2 weeks each. The levels of T lymphocyte subsets in the two groups were compared, and the incidence of adverse reactions in the two groups were observed. Results After treatment, the levels of CD3 ~ +, CD4 ~ + and CD8 ~ + in the observation group were significantly higher than those in the control group (68.84 ± 5.73), (44.14 ± 4.82)% and (47.15 ± 4.17)%, respectively ± 5.26)%, (35.28 ± 4.21)% and (38.61 ± 3.82)%, respectively (P <0.05). The adverse reactions of the observation group were 20.93%, 18.60% %, Compared with the control group 39.53%, 37.21% were significantly lower, the difference was statistically significant (P <0.05). Conclusion Oxaliplatin combined with capecitabine can significantly improve the level of T lymphocyte subsets, improve cellular immune function and relieve adverse reactions in postoperative patients with advanced gastric cancer.